Survivin, Survivin-2B, and Survivin-deltaEx3 expression in medulloblastoma: Biologic markers of tumour morphology and clinical outcome

J. R. Fangusaro, Y. Jiang, M. P. Holloway, H. Caldas, V. Singh, D. R. Boué, J. Hayes, R. A. Altura*

*Corresponding author for this work

Research output: Contribution to journalArticle

54 Scopus citations

Abstract

Survivin is an apoptotic inhibitor that is expressed at high levels in a variety of malignancies. Survivin has four known alternative splice forms (Survivin, Survivin-2B, Survivin-deltaExB, and Survivin-3B), and the recent literature suggests that these splice variants have unique functions and subcellular localisation patterns. We evaluated 19 fresh-frozen paediatric medulloblastomas for the expression of three Survivin isoforms by quantitative PCR. Survivin was most highly expressed when compared with normal cerebellar tissue. We also investigated Survivin protein expression in 40 paraffin-embedded paediatric medulloblastoma tumours by immunohistochemistry. We found a statistically significant association between the percentage of Survivin-positive cells and histologic subtype, with the large-cell-anaplastic variant expressing Survivin at higher levels than the classic subtype. We also found a statistically significant relationship between the percent of Survivin-positive cells in the tumours and clinical outcome, with higher levels of Survivin correlating with a worse prognosis. In summary, our study demonstrates a role for Survivin as a marker of tumour morphology and clinical outcome in medulloblastoma. Survivin may be a promising future prognostic tool and potential biologic target in this malignancy.

Original languageEnglish (US)
Pages (from-to)359-365
Number of pages7
JournalBritish Journal of Cancer
Volume92
Issue number2
DOIs
StatePublished - Jan 31 2005

Keywords

  • Apoptosis
  • Medulloblastoma
  • Survivin
  • Survivin isoforms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Survivin, Survivin-2B, and Survivin-deltaEx3 expression in medulloblastoma: Biologic markers of tumour morphology and clinical outcome'. Together they form a unique fingerprint.

  • Cite this

    Fangusaro, J. R., Jiang, Y., Holloway, M. P., Caldas, H., Singh, V., Boué, D. R., Hayes, J., & Altura, R. A. (2005). Survivin, Survivin-2B, and Survivin-deltaEx3 expression in medulloblastoma: Biologic markers of tumour morphology and clinical outcome. British Journal of Cancer, 92(2), 359-365. https://doi.org/10.1038/sj.bjc.6602317